EuroBiotech:​ ​More​ ​Articles​ ​of​ ​Note

A pile of newspapers

> Cassiopea (SWX:SKIN) committed to advancing its topical antibiotic CB-06-01. The decision follows publication of data from a 90-person proof-of-concept trial. Cassiopea thinks the data suggest the drug is worth pursuing as a treatment for moderate-to-severe acne, although it needs to carry out work on the formulation before moving into a Phase Ib dose-ranging study. Release

> GW Pharmaceuticals ($GWPH) revealed it will drop its listing on London’s AIM next month. The cannabinoid specialist has been on its home exchange since 2001, but, with its focus moving to Nasdaq since 2013, has decided it can save money by ditching the listing. GW Pharma has committed to keeping its headquarters in the United Kingdom. Reuters

> ObsEva outlined plans for a U.S. IPO. The Swiss women’s health specialist has yet to flesh out details of the timing and terms of the listing. ObsEva last raised money 11 months ago when it pulled in CHF 60 million ($60 million) in a Series B. New investors including New Enterprise Associates and OrbiMed joined with existing backers Sofinnova Partners, Novo Ventures and MS Ventures to put up the money. Release

> Hookipa Biotech landed a €4.16 million grant to advance its lead oncology candidate and related technologies. The Austrian biotech, which is helmed by former uniQure ($QURE) CEO Jörn Aldag, is working on a drug to treat human papillomavirus-associated head and neck cancer. Release

> Dilaforette detailed plans to change its name to Modus Therapeutics and IPO. The Swedish drug developer, which is part of Karolinska Development’s (STO:KDEV) stable of biotechs, has a treatment for sickle cell disease in Phase II. By going public, Modus hopes to secure money to support the advance of its lead candidate. Release

> Transgene (EPA:TNG) set out to raise €48 million ($53 million) through a rights issue. The French biotech wants the money to support its R&D plans through to the end of 2018. Seven clinical trials are in the works. With data readouts due to start rolling in from 2017 onward, Transgene thinks the rights issue will see it through to a time when it is in a better position to strike deals for its assets. Release